【摘要】：【背景和目的】:原發(fā)性支氣管肺癌是當(dāng)今世界發(fā)病率和死亡率最高的惡性腫瘤之一,嚴(yán)重威脅人類的健康和生命。隨著環(huán)境污染尤其是空氣污染的加劇,我國肺癌發(fā)病率持續(xù)快速上升,且有低齡化趨勢。盡管近年來手術(shù)、化療、靶向治療等綜合治療效果明顯改善,但其5年生存率仍較低。因此除了傳統(tǒng)的治療手段外,腫瘤的免疫治療以及腫瘤微環(huán)境的影響受到越來越多學(xué)者的關(guān)注。腫瘤相關(guān)性炎癥已經(jīng)成為腫瘤的“無限復(fù)制的潛能、促血管生成、對程序性細(xì)胞死亡的逃逸、生長信號(hào)的自給自足、對生長抑制劑的不敏感、組織侵犯和轉(zhuǎn)移”之外的“第七大特征”[1]。炎癥(inflammation)是機(jī)體抵御外界病原體侵襲以及各種化學(xué)、物理性損傷的免疫反應(yīng)。慢性炎癥可以促進(jìn)腫瘤的發(fā)生和發(fā)展,并參與腫瘤細(xì)胞的發(fā)生、生長和轉(zhuǎn)移的各病理過程。炎癥小體(inflammasome)是由胞漿內(nèi)模式識(shí)別受體(pattern recognition receptors,PRRs)參與組裝的多蛋白復(fù)合物,能啟動(dòng)和參與炎癥反應(yīng)的核心環(huán)節(jié)。NLRP3(NOD-like receptor family pyrin domain containing 3)炎癥小體是目前研究較多且能被多種刺激物活化的炎癥小體。文獻(xiàn)顯示NLRP3炎癥小體參與多種腫瘤(如黑色素瘤、肝癌、胃癌等)的進(jìn)展過程,但在不同的腫瘤中發(fā)揮的作用不同甚至相反,具有一定的細(xì)胞或組織特異性。因此,本實(shí)驗(yàn)將研究NLRP3炎癥小體活化對肺腺癌細(xì)胞株A549生物學(xué)特征的影響及其可能的作用機(jī)制,為臨床治療肺腺癌提供新的思路及理論基礎(chǔ)�！痉椒ā�:1.我們用細(xì)胞免疫熒光、western blot、酶聯(lián)免疫吸附試驗(yàn)(Enzyme-linked immunosorbent assay,ELISA)方法檢測在A549細(xì)胞中NLRP3炎癥小體是否能夠活化。2.用Ed U增殖d{入方法檢測NLRP3炎癥小體活化后對A549細(xì)胞增殖的影響。用Annexin V/PI染色流式細(xì)胞儀檢測NLRP3炎癥小體活化后對A549細(xì)胞凋亡的影響。此外,用慢病毒干擾(sh NLRP3)方法穩(wěn)定下調(diào)NLRP3表達(dá),caspase-1抑制劑z-YVAD-FMK抑制caspase-1,IL-18結(jié)合蛋白(interleukin-18binding protein,IL-18BP)、IL-1受體拮抗劑(IL-1receptor antagonist,IL-1Ra)阻斷IL-18、IL-1β信號(hào)通路,從這三個(gè)方面抑制NLRP3炎癥小體的活性后,用Ed U增殖d{入方法觀察細(xì)胞增殖情況的變化。用western blot方法檢測p-Akt、p-GSK-3β、p-ERK1/2、p-CREB等信號(hào)通路的變化。3.用細(xì)胞劃痕實(shí)驗(yàn)、transwell小室遷移實(shí)驗(yàn)檢測NLRP3炎癥小體活化后對A549細(xì)胞遷移的影響。用Matrigel侵襲實(shí)驗(yàn)檢測NLRP3炎癥小體活化后對A549細(xì)胞侵襲的影響。此外,從這三個(gè)方面抑制NLRP3炎癥小體的活性:即用慢病毒干擾(sh NLRP3)方法穩(wěn)定下調(diào)NLRP3表達(dá),caspase-1抑制劑z-YVAD-FMK抑制caspase-1,IL-18結(jié)合蛋白(IL-18BP)、IL-1受體拮抗劑(IL-1Ra)阻斷IL-18、IL-1β信號(hào)通路后,觀察細(xì)胞遷移、侵襲情況的變化。用western blot方法檢測Snail、E-cadherin等信號(hào)通路的變化�！窘Y(jié)果】:1.使用經(jīng)典的NLRP3炎癥小體刺激劑LPS+ATP后,細(xì)胞免疫熒光顯示在LPS+ATP組有較多的點(diǎn)狀沉積代表NLRP3和接頭蛋白ASC的結(jié)合,western blot顯示活性形式的capspe-1 p10明顯增高,ELISA顯示細(xì)胞外IL-18、IL-1β明顯增高,而在control組、LPS組、ATP組沒有出現(xiàn)這些結(jié)果,說明LPS聯(lián)合ATP可以在A549細(xì)胞中激活NLRP3炎癥小體。2.LPS+ATP活化NLRP3炎癥小體后促進(jìn)了A549細(xì)胞增殖,p-Akt、p-GSK-3β、p-ERK1/2、p-CREB明顯增高。在sh Ctrl細(xì)胞中,LPS+ATP同樣促進(jìn)細(xì)胞增殖及上調(diào)p-Akt、p-GSK-3β、p-ERK1/2、p-CREB,但在sh NLRP3細(xì)胞中,LPS+ATP的上述作用沒有顯現(xiàn),說明通過sh NLRP3穩(wěn)定下調(diào)NLRP3而抑制炎癥小體活性后可以逆轉(zhuǎn)LPS+ATP的作用。Caspase-1抑制劑z-YVAD-FMK部分抑制LPS+ATP的促增殖作用,使上調(diào)的p-Akt、p-GSK-3β、p-ERK1/2、p-CREB下降但仍高于control水平。單獨(dú)使用IL-18BP或IL-1Ra均可部分抑制LPS+ATP的促增殖作用,IL-18BP對Akt/GSK-3β信號(hào)通路的影響相對更大,IL-1Ra對ERK1/2信號(hào)通路的影響相對更大,聯(lián)合使用IL-18BP和IL-1Ra可以阻斷LPS+ATP的促增殖作用。3.Annexin V/PI染色流式細(xì)胞儀檢測結(jié)果顯示NLRP3炎癥小體活化對A549細(xì)胞的凋亡無明顯影響。4.NLRP3炎癥小體活化促進(jìn)了A549細(xì)胞遷移、侵襲。5.NLRP3炎癥小體對A549細(xì)胞遷移和侵襲的影響,可能的信號(hào)通路包括E-cadherin、Snail。LPS+ATP組,細(xì)胞E-cadherin表達(dá)下降,Snail表達(dá)升高。在sh Ctrl細(xì)胞中,LPS+ATP同樣促進(jìn)細(xì)胞遷移、侵襲及下調(diào)E-cadherin、上調(diào)Snail,但在sh NLRP3細(xì)胞中,LPS+ATP的上述作用沒有顯現(xiàn),說明通過sh NLRP3穩(wěn)定下調(diào)NLRP3而抑制炎癥小體活性后可以逆轉(zhuǎn)LPS+ATP的作用。Caspase-1抑制劑z-YVAD-FMK部分抑制LPS+ATP的促遷移、促侵襲作用,但使下降的E-cadherin上調(diào)至control水平、升高的Snail下調(diào)至control水平,而只是部分抑制了p-JNK、p-p38、p-ERK1/2的絲裂原活化蛋白激酶(Mitogen activated protein kinases,MAPK)信號(hào)通路。單獨(dú)使用IL-18BP或IL-1Ra均可部分抑制LPS+ATP的促遷移、促侵襲作用,使下降的E-cadherin上調(diào)、升高的Snail下調(diào),但仍與control組有明顯差異,而聯(lián)合使用IL-18BP和IL-1Ra可以阻斷LPS+ATP的促遷移、促侵襲作用,使E-cadherin、Snail變化至基礎(chǔ)水平�！窘Y(jié)論】:1.NLRP3炎癥小體活化可以促進(jìn)A549細(xì)胞增殖、遷移、侵襲,可能通過調(diào)節(jié)p-Akt、p-GSK-3β、p-ERK1/2、p-CREB、E-cadherin、Snail、MAPK等信號(hào)通路而發(fā)揮作用。2.NLRP3炎癥小體可以作為調(diào)節(jié)肺腺癌增殖、遷移、侵襲的細(xì)胞內(nèi)信號(hào),可能成為肺癌潛在的治療靶點(diǎn)。
[Abstract]:BACKGROUND AND OBJECTIVE: Primary bronchogenic carcinoma (PBC) is one of the most common malignant tumors with the highest morbidity and mortality in the world today, which seriously threatens human health and life. With the aggravation of environmental pollution, especially air pollution, the incidence of lung cancer in China continues to rise rapidly and tends to be younger. However, the 5-year survival rate is still low. Therefore, in addition to the traditional treatment, tumor immunotherapy and the influence of tumor microenvironment have attracted more and more scholars'attention. Inflammation is the body's immune response to external pathogens and various chemical and physical injuries. Chronic inflammation can promote the occurrence and development of tumors and participate in tumor cells. Inflammatory bodies (inflammasomes) are polyprotein complexes assembled by intracytoplasmic pattern recognition receptors (PRRs), which can initiate and participate in the core of inflammation. Inflammatory bodies of NLRP3 have been shown to be involved in the progression of various tumors, such as melanoma, hepatocellular carcinoma, gastric cancer, etc. However, they play different or even opposite roles in different tumors and have certain cell or tissue specificity. [Methods] 1. We detected NLRP3 inflammation in A549 cells by immunofluorescence, Western blot and enzyme-linked immunosorbent assay (ELISA). The effect of activation of NLRP3 inflammatory bodies on the proliferation of A549 cells was detected by Ed U proliferative d{entry method. The effect of activation of NLRP3 inflammatory bodies on the apoptosis of A549 cells was detected by Annexin V/PI staining flow cytometry. In addition, the expression of NLRP3 was stably down-regulated by lentivirus interference (sh NLRP3), and the expression of Caspase-1 inhibitor z-YVAD-1 was down-regulated by Caspase-1 inhibitor z-YVAD-PI. FMK inhibited caspase-1, IL-18 binding protein (IL-18BP) and IL-1 receptor antagonist (IL-1Ra) blocked IL-18 and IL-1 beta signaling pathways. After inhibiting the activity of NLRP3 inflammatory bodies from these three aspects, the proliferation of NLRP3 cells was observed by Ed U proliferating D {entry method. Changes of Akt, p-GSK-3beta, p-ERK1/2, p-CREB signaling pathways. 3. The effects of activation of NLRP3 inflammatory bodies on the migration of A549 cells were detected by cell scratch test and Transwell chamber migration test. Matrigel invasion test was used to detect the effects of activation of NLRP3 inflammatory bodies on the invasion of A549 cells. Inhibitory effect of Caspase-1 inhibitor z-YVAD-FMK on caspase-1, IL-18 binding protein (IL-18BP) and IL-1 receptor antagonist (IL-1Ra) on IL-18 and IL-1 beta signaling pathways was observed. The changes of cell migration and invasion were detected by Western blot. Changes of pathway. [Results] 1. After the use of LPS + ATP, the classical inflammation body stimulator of NLRP3, more dot-like deposits in LPS + ATP group represented the binding of NLRP3 and adaptor protein ASC. Western blot showed that the active form of capspe-1 P10 was significantly increased. ELISA showed that extracellular IL-18 and IL-1 beta were significantly increased, while in control group, more dot-like deposits represented the binding of NLRP3 and adaptor protein ASC. LPS + ATP could activate NLRP3 inflammation corpuscle in A549 cells. 2. LPS + ATP activated NLRP3 inflammation corpuscle promoted A549 cell proliferation, p-Akt, p-GSK-3beta, p-ERK1/2, p-CREB increased significantly. LPS + ATP also promoted cell proliferation and up-regulated p-Akt, p-GSK-3beta, p-ERK1/2, p-CREB in SH Ctrl cells. However, the above-mentioned effects of LPS+ATP did not appear in SH NLRP3 cells, suggesting that the inhibition of inflammatory corpuscle activity by stably down-regulating NLRP3 by SH NLRP3 could reverse the effect of LPS+ATP. Caspase-1 inhibitor z-YVAD-FMK partially inhibited the proliferation of LPS+ATP, resulting in the up-regulation of p-Akt, p-GSK-3beta, p-ERK1/2 and p-CREB levels. IL-18BP or IL-1Ra alone can partially inhibit the proliferation of LPS+ATP. IL-18BP has a greater effect on Akt/GSK-3 beta signaling pathway, and IL-1Ra has a greater effect on ERK1/2 signaling pathway. Combined use of IL-18BP and IL-1Ra can block the proliferation of LPS+ATP. 3. Annexin V/PI staining flow cytometry showed that NLRP could inhibit the proliferation of LPS+ATP. Activation of NLRP3 promotes migration of A549 cells. Invasion of NLRP3 promotes migration and invasion of A549 cells. Possible signaling pathways include E-cadherin, Snail.LPS+ATP, decreased expression of E-cadherin and increased expression of Snail. TP also promoted cell migration, invasion and down-regulation of E-cadherin and up-regulation of Snail, but LPS+ATP did not show the above effect in SH NLRP3 cells, suggesting that inhibiting the activity of inflammatory corpuscles by stably down-regulating NLRP3 could reverse the effect of LPS+ATP. Caspase-1 inhibitor z-YVAD-FMK partially inhibited the migration of LPS+ATP and promoted the invasion of SH NLRP3 cells. The decreased E-cadherin was up-regulated to the control level, the elevated Snail was down-regulated to the control level, but only partially inhibited the mitogen-activated protein kinases (MAPK) signaling pathway of p-JNK, p-p38, p-ERK1/2. The combination of IL-18BP and IL-1Ra can block the migration and invasion of LPS+ATP, and make E-cadherin and Snail change to the basic level. [Conclusion] 1. The activation of NLRP3 inflammatory bodies can promote the proliferation, migration and invasion of A549 cells, possibly through the regulation of P. N-Akt, p-GSK-3beta, p-ERK1/2, p-CREB, E-cadherin, Snail, MAPK and other signaling pathways play a role.
【學(xué)位授予單位】：南京醫(yī)科大學(xué)
【學(xué)位級別】：博士
【學(xué)位授予年份】：2015
【分類號(hào)】：R734.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王振磊;孫萍萍;李天曉;黎曙霞;;白頭翁湯激活NLRP3炎癥小體治療炎癥性腸病的研究[J];中藥材;2012年08期

2 鈕憶欣;蘇青;;NLRP3的炎性反應(yīng)在2型糖尿病中的作用[J];醫(yī)學(xué)綜述;2011年02期

3 宋智;姜瀾;林正梅;;NLRP3及其在口腔疾病中的研究進(jìn)展[J];中華口腔醫(yī)學(xué)研究雜志(電子版);2012年05期

4 毛開睿;孫兵;;NLRP3炎癥小體研究進(jìn)展[J];現(xiàn)代免疫學(xué);2011年01期

5 王定坤;陳廣;陸付耳;;NLRP3炎癥小體與2型糖尿病的研究進(jìn)展[J];生理科學(xué)進(jìn)展;2014年02期

6 隋永恒;連敏;華靜;;體內(nèi)外高脂對肝臟NLRP3炎性小體相關(guān)基因表達(dá)的影響[J];胃腸病學(xué);2014年01期

7 張懿;劉磊;劉韻資;張婷;蔣春雷;;NLRP3炎性小體研究新進(jìn)展[J];現(xiàn)代生物醫(yī)學(xué)進(jìn)展;2014年09期

8 蔣建燁;田nI;張艷;;NLRP3炎癥體與炎癥性疾病[J];微生物學(xué)免疫學(xué)進(jìn)展;2012年01期

9 宋麗敏;尚游;吳艷;;NLRP3炎性小體在中樞神經(jīng)系統(tǒng)炎癥中的作用[J];中風(fēng)與神經(jīng)疾病雜志;2014年04期

10 ;生化與細(xì)胞所研究發(fā)現(xiàn)TRIM30負(fù)性調(diào)控NLRP3炎癥小體的激活[J];東北農(nóng)業(yè)大學(xué)學(xué)報(bào);2010年11期

相關(guān)會(huì)議論文 前4條

1 鐘琳曄;楊汀;;NLRP3炎癥小體及其激活產(chǎn)物在慢性阻塞性肺疾病中的作用研究進(jìn)展[A];中華醫(yī)學(xué)會(huì)呼吸病學(xué)年會(huì)——2013第十四次全國呼吸病學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2013年

2 王振磊;孫萍萍;李天曉;黎曙霞;;白頭翁湯激活NLRP3炎癥小體治療炎癥性腸病的研究[A];2013年廣東省藥師周大會(huì)論文集[C];2013年

3 黃馨;軒東英;章錦才;;NLRP3信號(hào)通路在牙周炎與糖尿病相互關(guān)系中的研究[A];第十次全國牙周病學(xué)學(xué)術(shù)會(huì)議論文摘要匯編[C];2014年

4 王彥君;龔國清;陳建軍;陳刪;牛永芝;熊利燕;孔維佳;;慢性鼻竇炎伴與不伴鼻息肉與NLRP3炎癥小體的關(guān)系[A];中華醫(yī)學(xué)會(huì)第十三次全國耳鼻咽喉——頭頸外科學(xué)術(shù)會(huì)議論文匯編[C];2013年

相關(guān)博士學(xué)位論文 前10條

1 王玢tx;新城疫病毒激活NLRP3炎癥小體及其作用[D];中國農(nóng)業(yè)科學(xué)院;2016年

2 孔祥;NLRP3炎癥小體在糖化終末產(chǎn)物誘導(dǎo)的胰島β細(xì)胞損傷中的作用研究[D];上海交通大學(xué);2015年

3 肖孟景;NLRP3炎性體在深二度燒傷創(chuàng)面早期加深中的作用及自噬對其的調(diào)控[D];中國人民解放軍醫(yī)學(xué)院;2016年

4 潘楊;NLRP3炎癥小體在帕金森病神經(jīng)炎癥中的作用及治療學(xué)意義研究[D];南京醫(yī)科大學(xué);2016年

5 張懿;NLRP3炎性小體在抑郁樣行為中的作用及分子機(jī)制[D];第二軍醫(yī)大學(xué);2016年

6 劉海亮;抑制NLRP3炎性體聯(lián)合CIK細(xì)胞治療胰腺癌的實(shí)驗(yàn)研究[D];中國人民解放軍醫(yī)學(xué)院;2016年

7 余琛琳;基于NLRP3炎癥小體的無煙氣煙草水提取物的肝臟毒性作用及機(jī)制研究[D];第二軍醫(yī)大學(xué);2016年

8 謝強(qiáng);miR-223抑制佐劑性關(guān)節(jié)炎大鼠巨噬細(xì)胞NLRP3炎癥小體介導(dǎo)炎癥因子分泌的分子機(jī)制研究[D];安徽醫(yī)科大學(xué);2016年

9 王艷麗;NLRP3炎癥小體活化對肺腺癌細(xì)胞A549增殖、遷移、侵襲的影響及其作用機(jī)制[D];南京醫(yī)科大學(xué);2015年

10 吳劍波;NLRP3炎性體對機(jī)械通氣所致肺損傷的調(diào)節(jié)作用[D];山東大學(xué);2014年

相關(guān)碩士學(xué)位論文 前10條

1 謝海龍;2型糖尿病患者外周血單個(gè)核細(xì)胞NLRP3炎性體mRNA表達(dá)和炎性因子水平與動(dòng)脈粥樣硬化相關(guān)性研究[D];長江大學(xué);2015年

2 沈文文;miR-20a對AA大鼠模型滑膜細(xì)胞中NLRP3炎癥小體的調(diào)控作用及其機(jī)制的研究[D];安徽醫(yī)科大學(xué);2015年

3 徐曉艷;TIM-4與2型糖尿病的相關(guān)性及對NLRP3炎性體的抑制效應(yīng)[D];山東大學(xué);2015年

4 許倡濤;TXNIP介導(dǎo)的心肌微血管內(nèi)皮細(xì)胞NLRP3炎性小體活化在心肌缺血再灌注損傷中的機(jī)制研究[D];第四軍醫(yī)大學(xué);2015年

5 魯理;1,25(OH)2D3通過抑制NLRP3炎癥小體激活保護(hù)高糖誘導(dǎo)的視網(wǎng)膜血管內(nèi)皮細(xì)胞功能障礙[D];蚌埠醫(yī)學(xué)院;2015年

6 周航;小檗堿通過抑制NLRP3炎癥小體活化改善小鼠胰島素抵抗[D];南京大學(xué);2014年

7 楊加偉;糖皮質(zhì)激素調(diào)控NLRP3炎性體表達(dá)在ALI/ARDS中的作用和機(jī)制[D];蘇州大學(xué);2016年

8 尹聰聰;NLRP3炎癥小體信號(hào)通路基因多態(tài)性與骨髓增生異常綜合征易感性的關(guān)聯(lián)研究[D];山東大學(xué);2016年

9 許鍵;NLRP3炎癥小體與心房顫動(dòng)的相關(guān)性研究[D];廣西醫(yī)科大學(xué);2016年

10 張維康;NLRP3炎癥復(fù)合體在呼吸機(jī)相關(guān)性肺損傷中的作用機(jī)制研究[D];廣西醫(yī)科大學(xué);2016年

，

本文編號(hào)：2231757